A Metal-Polyphenol-Based Antidepressant for Alleviating Colitis-Associated Mental Disorders

Area of Science:

• Nanomedicine
• Neuroscience
• Gastroenterology

Background:

• Inflammatory bowel diseases (IBD) are linked to psychosocial issues like depression and anxiety.
• Current antidepressants are often ineffective for IBD-related mental health problems due to gut-brain axis dysfunction.

Purpose of the Study:

• To develop and evaluate a metal-polyphenol-based antidepressant (CSMTC) for treating mental disorders in experimental colitis.
• To investigate CSMTC's mechanism of action via the microbiota-gut-brain axis.

Main Methods:

• CSMTC, containing antioxidant enzymes and a tannic acid-cerium ion network, was administered orally to dextran sulfate sodium-induced colitis mice.
• Evaluated effects on colonic redox balance, intestinal barrier, gut microbiota, blood-brain barrier integrity, and systemic immunity.
• Assessed behavioral changes, neuroinflammation, neural plasticity, and neurotransmitter homeostasis in the hippocampus.

Main Results:

• CSMTC restored colonic redox balance, strengthened the intestinal barrier, modulated gut microbiota, and maintained blood-brain barrier integrity.
• CSMTC significantly alleviated depression-like behaviors in colitis mice.
• Mechanism involved reducing neuroinflammation, enhancing hippocampal plasticity, and restoring neurotransmitter balance via the microbiota-gut-brain axis.

Conclusions:

• CSMTC demonstrates therapeutic potential for IBD-associated mental disorders by modulating the microbiota-gut-brain axis.
• This metal-polyphenol nanodrug offers a promising strategy for treating inflammation-related complications and mental health issues.